Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dr. Reddy's Laboratories Ltd (RDY)
NYSE:RDY
RESEARCH TOOLSreports
Holding RDY?
Track your performance easily
Earnings Data
Report Date
Jan 23, 2025TBA Not Confirmed
Period Ending
2025 (Q3)Consensus EPS Forecast
0.21Last Year’s EPS
0.2Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 26, 2018
|% Change Since: 0.68%
|Next Earnings Date:Jul 26, 2018
Earnings Call Sentiment|Positive
The earnings call reflects a strong overall performance with significant revenue growth and strategic acquisitions. However, there are some challenges, including sequential declines in North America sales, increased SG&A expenses, and impairment losses.Company Guidance
During the Q2 FY '25 earnings call for Dr. Reddy's Laboratories, the executives highlighted a strong financial performance marked by a 17% year-over-year increase in consolidated revenues, reaching INR 8,016 crores (USD 957 million). The gross profit margin stood at 59.6%, reflecting a 92 basis point improvement from the previous year, despite a slight sequential decline due to product mix changes. SG&A expenses rose by 22% year-over-year, attributed to new business initiatives and acquisition-related costs, accounting for 28.7% of sales. R&D spending increased to INR 727 crores, or 9.1% of sales, as the company focused on developing a pipeline of complex products, including small molecules and biosimilars. EBITDA for the quarter was INR 2,280 crores, with margins at 28.4% of sales, slightly reduced year-over-year due to acquisition costs. Profit before tax was INR 1,917 crores, with an effective tax rate of 30%, leading to a profit after tax of INR 1,342 crores, translating to a PAT margin of 16.7%. The company maintained a net cash surplus of INR 1,889 crores, even after a significant upfront payment for the acquisition of an NRT portfolio.Record Revenue Growth
Consolidated revenues grew by 17% year-over-year and 4% sequentially, reaching INR 8,016 crores (USD 957 million).
Strong North America Generics Performance
North America Generics business recorded revenues of $445 million, showing a year-over-year growth of 16% despite sequential declines due to supply chain adjustments.
Significant R&D Investment
R&D spend was INR 727 crores (USD 87 million), increasing by 33% year-over-year, focusing on developing complex value-accretive products.
Successful Acquisitions
Completed acquisition of Nicotinell and related brands and operationalized a venture with Nestlé for nutraceuticals in India.
Regulatory Approvals
Secured marketing authorization for rituximab biosimilar in Europe and received USFDA approval for IND for AUR-112.
---
RDY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
RDY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 05, 2024 | $14.80 | $14.61 | -1.28% |
| May 07, 2024 | $14.90 | $14.20 | -4.70% |
| Jan 30, 2024 | $13.94 | $13.81 | -0.93% |
| Oct 27, 2023 | $12.86 | $12.94 | +0.62% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Dr. Reddy's Laboratories Ltd (RDY) report earnings?
Dr. Reddy's Laboratories Ltd (RDY) is schdueled to report earning on Jan 23, 2025, TBA Not Confirmed.
What is Dr. Reddy's Laboratories Ltd (RDY) earnings time?
Dr. Reddy's Laboratories Ltd (RDY) earnings time is at Jan 23, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RDY EPS forecast?
RDY EPS forecast for the fiscal quarter 2025 (Q3) is 0.21.
---